RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

The issue of carving out indications has been discussed in the past.It's unlikely. Which is why I have mentioned that a deal's value will not be just in the cash, but which molecules are tied up in a deal. In general, companies don't want other companies working with the same molecule, because if someone else screws up with safety, for example, it taints everyone.

The question of who gets control over which molecules is part of the negotiation. Neurocrine Biosciences was a good example of how this can be orchestrated: They licensed an early set of CRF antagonists to Janssen, they failed. Neurocrine turned around and licensed a newer, "better" set to GSK. "Better" perhaps, but the first couple iterations of the GSK group were dropped from development, and the third failed in social anxiety. Lesson: You can't necessarily be sure of how compounds you think will be superior will actually behave in humans.

NeuroInvestment